Effects of testosterone treatment on plasma melatonin levels in male hypogonadism

Özata, Metịn; Beyhan, Zeynel

doi:10.1046/j.1365-2265.1998.00497.x

Cited by 2 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, other factors are responsible for the melatonin release in patients with hypogonadism. This suggestion is supported by some studies, which found that testosterone supplementation did not influence melatonin secretion (Leibenluft et al, 1997;Ozata & Beyhan, 1998). Ozata & Beyhan (1998) demonstrated that patients with idiopathic hypogonadotropic hypogonadism have increased early morning melatonin levels, which are not influenced by short-term testosterone treatment.…”

Section: Discussionmentioning

confidence: 78%

See 1 more Smart Citation

Altered melatonin secretion in hypogonadal men: clinical evidence

et al. 2005

View full text Add to dashboard Cite

The pineal gland, through the rhythmic production of melatonin, seems to play an important role in the control of the reproductive function of many vertebrate species. In contrast, the effects of the pineal gland in humans and the relationship between gonadotropins and melatonin secretion are not yet clarified. On the basis of these considerations, the aim of the present study was to clarify whether melatonin serum concentrations were altered in males with different hypothalamo-pituitary-gonadal disturbances, in comparison to normal individuals. We have studied 36 individuals divided into three groups according to their gonadotropin status: normals, hypogonadotropic hypogonadism and hypergonadotropic hypogonadism. They were submitted to blood sample withdrawal at 03.00, 11.00 and 19.00 h for melatonin determination according to a radioimmunological method, without extraction of the sample. The results obtained in the present study suggest the existence of an interaction between the pituitary and the pineal gland. In fact, in the case of hypersecretion of gonadotropins, nocturnal melatonin release is reduced, while night melatonin secretion is increased in the opposite situation (hypogonadotropic hypogonadism). Both these endocrine pathologies are characterized by a reduced sexual steroid secretion; for that reason, this reduction cannot be regarded as responsible for the two opposite dysfunctions of melatonin release. In conclusion, our study shows that darkness-dependent release of melatonin in males with hypogonadotropic hypogonadism is significantly higher in comparison with the healthy men, while it is significantly reduced in patients with hypergonadotropic hypogonadism. A strong significant negative correlation is also found between gonadotropins and melatonin release.

show abstract

Section: Discussionmentioning

confidence: 78%

“…, 1997; Ozata & Beyhan, 1998). Ozata & Beyhan (1998) demonstrated that patients with idiopathic hypogonadotropic hypogonadism have increased early morning melatonin levels, which are not influenced by short‐term testosterone treatment. This observation is in accordance with the data of our study.…”

Section: Discussionmentioning

confidence: 98%

Altered melatonin secretion in hypogonadal men: clinical evidence

et al. 2005

View full text Add to dashboard Cite

show abstract

Plasma Melatonin Concentration before and during Testosterone Replacement in Klinefelter’s Syndrome: Relation to Hepatic Indolamine Metabolism and Sympathoadrenal Activity

Çağlayan¹,

Özata²,

Özışık³

et al. 2001

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

The mechanisms leading to alterations in plasma melatonin (MT) levels with testosterone replacement in Klinefelter's syndrome (KS) remain elusive. We investigated early morning plasma MT levels, urinary 6-sulfatoxymelatonin (6-SM) levels, and urinary catecholamine levels before and 6 months after testosterone treatment in 31 patients with KS and 20 healthy males to demonstrate whether alterations in plasma MT levels in such patients are due to subtle changes in sympathoadrenal activity and/or alterations in the hepatic indolamine metabolism influenced by testosterone replacement. The plasma MT level was measured by RIA. The sensitivity of the test was 10.7 pmol/L. The 6-SM level was measured by enzyme-linked immunosorbent assay. Urinary catecholamines were determined by high performance liquid chromatography. The pretreatment mean plasma MT level was insignificantly higher in the patient group than in the control group (72.57 +/- 74.82 vs. 42.37 +/- 29.02 pmol/L; z = -1.218; P = 0.223). The pretreatment urinary 6-SM and norepinephrine (NE) levels were significantly lower and, the epinephrine (E) and dopamine levels were insignificantly lower in the patient group than those in the control group [6-SM, 76.54 +/- 31.92 vs. 125.49 +/- 50.16 nmol/L (z = -3.727; P < 0.001); NE, 120.79 +/- 58.33 vs. 178.84 +/- 81.61 nmol/day (z = -2.585; P = 0.01); E, 31.27 +/- 27.42 vs. 34.65 +/- 28.33 nmol/day (z = -0.39; P: = 0.692); dopamine, 1577.02 +/- 863.02 vs. 1812.32 +/- 677.59 nmol/day (z = -1.03, P = 0.308)]. After testosterone replacement, plasma MT levels were significantly decreased (72.57 +/- 74.82 vs. 24.73 +/- 23.61 pmol/L; z = -4.29; P < 0.001), and urinary 6-SM, NE, E, and dopamine levels were significantly increased [6-SM, 25.04 +/- 10.44 vs. 40.05 +/- 17.65 ng/mL (z = -4.78; P < 0.001); NE, 120.78 +/- 58.33 vs. 154.08 +/- 61.35 nmol/day (z = -4.27; P < 0.001); E, 31.27 +/- 27.42 vs. 40.74 +/- 30.04 nmol/day (z = -4.22; P < 0.001); dopamine, 1577.02 +/- 863.02 vs. 2162.67 +/- 823.15 (z = -6.127; P < 0.001)]. There was no relation between plasma MT levels, urinary 6-SM, and catecholamine levels and levels of gonadotropins or gonadal steroids either before or after treatment. We demonstrate that in untreated KS, plasma MT levels tend to be higher than those in normal controls, whereas those of the melatonin metabolite 6-SM and those of NE in urine tend to be lower. After testosterone treatment, however, plasma MT levels fall significantly, whereas urinary levels of 6-SM and NE rise. Our data show that the effect of testosterone is mediated by enhanced metabolism of melatonin, not by any effect on net sympathetic outflow, and that the increase in plasma melatonin in untreated KS patients also results from an alteration in the rate of melatonin metabolism and not from increased net sympathetic activity.

show abstract

Effects of testosterone treatment on plasma melatonin levels in male hypogonadism

Cited by 2 publications

References 22 publications

Altered melatonin secretion in hypogonadal men: clinical evidence

Altered melatonin secretion in hypogonadal men: clinical evidence

Plasma Melatonin Concentration before and during Testosterone Replacement in Klinefelter’s Syndrome: Relation to Hepatic Indolamine Metabolism and Sympathoadrenal Activity

Contact Info

Product

Resources

About